The purpose of this study is to investigate whether zoledronic acid-loaded bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease local recurrence in patients with giant cell bone tumor following intralesional curettage surgery. The hypothesis is that patients with local administration of zoledronic acid to the bone cement has lower relapse rate compared those with traditional bone cement(gentamicin PMMA ).
patients with primary resectable GCT of bone
lesion amenable to reconstruction (intralesional curettage) defined as having at least one intact column of bone after removal
no previous systemic bisphosphonate or denosumab therapy
with expected longer than 18 months of survival time
patients with recurrent GCT or extensive GCT which is impossible or inappropriate to use curettage surgery due to its "unresectable" nature.
conduct unexpected surgery at other center
the primary goal for surgery is revision
patient conduct en-bloc/wide resection instead of curettage surgery